Stocks · Health care · Pharmaceutical Preparations

CytomX Therapeutics, Inc.

CTMX Clue Score50
United States Fiscal year ends December CIK 0001501989 Results filed 5 Nov 2026

What the insiders did Net selling

By person

7 insiders · 6 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Sean A. McCarthy
CEO
—
$1.23M (2) scheduled
−$1.23M
2,066,813
$6.30M
+25.6%
Marcia Belvin
SVP, Chief Scientific Officer
—
$202.27K (1)
−$202.27K
300,760
$917.32K
+66.5%
Yu-Waye Chu
Chief Medical Officer
—
$136.68K (1)
−$136.68K
189,446
$577.81K
+621.7%
Christopher Ogden
Chief Financial Officer
—
$129.06K (2)
−$129.06K
295,324
$900.74K
+173.3%
Lloyd A Rowland
General Counsel
—
—
—
120,594
$367.81K
−7.8%
Alejandra Carvajal
Chief Legal Officer
—
—
—
100,000
$305.00K
—
Rachael Lester
Chief Business Officer
—
—
—
20,000
$61.00K
—

No percentages here. This company's share count has moved by a factor of 2.7 over the window, from 80,621,293 to 217,899,284 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.